Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01) | RFA AR 18 002

Opportunity Information: Apply for RFA AR 18 002

The National Institutes of Health, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), offered the RFA-AR-18-002 funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)." It is a discretionary NIH grant mechanism (R01) in the health funding activity category (CFDA 93.846) designed to support time-sensitive mechanistic studies that can be carried out alongside an already active interventional clinical trial. The core idea is to capitalize on an existing trial that is already enrolling or following participants and already has the operational infrastructure in place, rather than building a new cohort or trial from scratch.

The FOA specifically targets ancillary studies that are mechanistic in nature and tied to NIAMS mission areas, meaning research that deepens understanding of biological mechanisms relevant to diseases and conditions within NIAMS' portfolio (for example, arthritis and rheumatic diseases, musculoskeletal disorders, and skin diseases). The ancillary project is expected to leverage what the parent trial already provides: a cohort of well-characterized patients, established trial infrastructure, existing clinical data streams, and access to biological samples (or the ability to collect them within the trial context). By adding a focused mechanistic component to a functioning clinical trial, the NIH aims to extract more scientific value from prior investments and produce insights that might not be achievable through standard clinical endpoints alone.

A defining feature of this opportunity is speed. Applications were intended to go through an accelerated review and award process, reflecting the fact that these ancillary studies are often time-bound. If a parent trial is already underway, there may be a narrow window to add specimen collection, specialized assays, imaging, or other mechanistic measurements before treatment arms conclude, participants roll off, or key timepoints pass. This accelerated pathway is meant to help investigators act while the parent trial can still support the additional work.

In practical terms, the NIH objective here is to provide a flexible mechanism to "piggyback" mechanistic questions onto ongoing interventional trials, thereby maximizing return on existing investments. The ancillary study should enhance the parent project rather than distract from it, adding scientific depth and increasing the overall value of the clinical trial. NIAMS emphasized that successful projects should improve the research community's understanding of disease processes or organ systems relevant to NIAMS, and that the mechanistic findings may point toward new targets for diagnosis, treatment, or prevention. In other words, the ancillary study is expected to help explain why an intervention works or does not work, identify biomarkers or pathways associated with response, clarify disease biology, or otherwise translate clinical trial participation into deeper mechanistic knowledge.

Eligibility was broad and included many common NIH-eligible applicant types: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other organizations. The FOA also highlighted additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, tribal governments that are not federally recognized, and U.S. territories or possessions.

At the same time, the FOA drew clear boundaries around foreign participation. Non-domestic (non-U.S.) entities (foreign institutions) were not eligible to apply as applicant organizations, and non-domestic components of U.S. organizations were also not eligible. However, "foreign components" as defined under the NIH Grants Policy Statement were allowed, meaning a U.S. applicant could include certain types of foreign involvement when it meets NIH policy definitions and requirements, even though a foreign institution could not serve as the primary applicant.

Administrative details included an award ceiling listed as $300,000, with an original closing date of 2018-04-02 and a creation date of 2017-05-01. Overall, the opportunity was structured for investigators who can demonstrate that an existing interventional clinical trial provides the right platform, participants, and operational capacity to support add-on mechanistic research quickly and efficiently, and that the proposed ancillary work will meaningfully expand what can be learned from the parent trial in NIAMS-relevant disease areas.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2017-05-01.
• Applicants must submit their applications by 2018-04-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 18 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: